Dermatology Times

MARCH 29, 2024

Brian Kim, MD, explores long-term ruxolitinib data and combination therapies in the treatment of pediatric atopic dermatitis.

Therapy 36

Therapy Dermatitis Treatments 36

US Dermatologt Partners

NOVEMBER 25, 2023

Atopic dermatitis (AD) is a multifaceted condition that can significantly impact a patient’s quality of life. I think that dermatitis started showing up once my psoriasis started showing up,” Dean said. “As As a physician, I have to do a better job intervening here [and] switch our systemic therapies.”

Dermatitis 36

Dermatitis Therapy Networking Treatments 36

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

Dermatology Times

SEPTEMBER 20, 2023

Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.

Therapy 41

Therapy Dermatitis Treatments 41

US Dermatologt Partners

AUGUST 23, 2023

Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. From identifying triggers and creating a customized daily skincare plan to discussing medications and other treatments, a dermatologist can help you achieve and maintain healthy skin.” Millions of people in the U.S.

Eczema 36

Eczema Dermatitis Management Skin Health 36

Dermatology Times

MAY 30, 2024

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative. (..)

Dermatitis 72

Dermatitis Therapy Management Treatments 72

First Derm

FEBRUARY 6, 2024

Online Dermatologist Topical Steroid Withdrawal: Causes, Symptoms, and Treatments What is Topical Steroid Withdrawal? Professional Guidance is Essential : Consulting healthcare professionals is vital for obtaining an accurate diagnosis, understanding your condition, and developing a personalized treatment plan. Dermatitis.

Treatments 59

Treatments Dermatitis Management Skin Issues 59

First Derm

APRIL 5, 2024

Factors affecting adherence include socioeconomic status, treatment complexity, and the specific skin condition being treated. Strategies to improve adherence range from using eHealth tools and educational resources to simplifying treatment regimens.

Dermatology 59

Dermatology Treatments Education Medical 59

Dermatology Times

APRIL 1, 2024

Brad Glick, DO, MPH, says it is essential to consider patient lifestyles when choosing atopic dermatitis therapies.

Treatments 36

Treatments Dermatitis Therapy 36

Dermatology Times

JULY 1, 2024

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

AUGUST 12, 2024

This week’s collection of the latest dermatologic studies includes the impact of isotretinoin treatment on femoral cartilage thickness, cystic fibrosis dermatitis arthritis syndrome, the role of intratumoral therapies for cutaneous melanoma, and fractional pigment toning for treating benign epidermal pigmented lesions.

Dermatitis 41

Dermatitis Therapy Dermatology Treatments 41

The Dermatology Digest

MARCH 13, 2024

Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.

Treatments 36

Treatments Dermatitis Dermatology Eczema 36

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.

Treatments 36

Treatments Pharmaceutical Dermatitis Eczema 36

The Dermatology Digest

MARCH 10, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE.

Treatments 36

Treatments Dermatitis Eczema Dermatology 36

First Derm

MARCH 22, 2024

Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Who’s at Risk : Affects both genders and all ages, but more common in infants and children with atopic dermatitis.

Eczema 52

Eczema Dermatitis Clinic Medical 52

First Derm

JUNE 23, 2024

1] Three main categories of eczema are atopic eczema, contact dermatitis and stasis dermatitis. Eczema severity varies from person to person, so the treatment should be tailored to individual needs. While one product used in treatment may suit one individual, it might cause severe reactions in another.

Eczema 59

Eczema Ingredients Dermatitis Irritation 59

The Dermatology Digest

JUNE 12, 2024

A human, monoclonal antibody targeting the interleukin (IL)-13 cytokine, tralokinumab is currently indicated in patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dermatitis 36

Dermatitis Injections Eczema Therapy 36

The Dermatology Digest

MARCH 13, 2024

Silverberg, MD, Chief of Pediatric Dermatology for the Mount Sinai Health System in New York, reviews the rationale for treating Molluscum Contagiosum and shares updates on available treatments including disruptive techniques and the newly approved Zelsuvmi (berdazimer topical gel, 10.3% (Zelsuvmi, Ligand) cantharidin (Ycanth, Verrica).

Treatments 36

Treatments Dermatitis Dermatology Eczema 36

Dermatology Times

JUNE 3, 2024

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.

Dermatitis 36

Dermatitis Therapy Treatments 36

The Dermatology Digest

JUNE 14, 2024

The late-breaking data, presented at the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois, showed that upadacitinib bested dupilumab for all ranked secondary endpoints of LEVEL-UP, including complete skin clearance and rapid resolution of itching in patients with severe itch.

Dermatitis 36

Dermatitis Eczema Therapy Clinic 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

First Derm

DECEMBER 4, 2023

Dry skin is a very common problem in people with atopic dermatitis, a chronic inflammatory skin condition characterized by patches of itchy, dry, red, and inflamed skin. Atopic dermatitis (eczema) characterized by itchy patches of red, inflamed, dry skin. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis.

Dry Skin 92

Dry Skin Moisturization Eczema Dermatitis 92

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 36

Eczema Dermatitis Safety Therapy 36

First Derm

JULY 2, 2024

Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.

Eczema 59

Eczema Management Dermatitis Irritation 59

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

West Lake Dermatology

AUGUST 2, 2023

Not all blemishes are alike, and effective treatment plan for any skin issue requires a proper diagnosis. Standard acne treatments do little to help with the blemishes and bumps caused by fungal acne as their underlying cause is unique. Schedule a follow-up appointment if the blemishes return after treatment.

Treatments 36

Treatments Oily Skin Dermatitis Medical 36

The Dermatology Digest

MARCH 11, 2024

Tralokinumab (Adbry, Leo Pharma) provides stable long-term control of atopic dermatitis (AD), new research shows. Patients were permitted to enter ECZTEND after completion of the parent trial regardless of their treatment response or whether they were treated with Adbry or placebo. tells TDD.

Dermatitis 36

Dermatitis Eczema Dermatology Consultation 36

The Dermatology Digest

MARCH 11, 2024

Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.

Dermatitis 69

Dermatitis Eczema Dermatology Pharmaceutical 69

Lipgloss and Aftershave

SEPTEMBER 3, 2024

Event Education by Skincare Industry Leaders These speakers will provide attendees with actionable insights into how to elevate client care by incorporating lifestyle changes, personalized treatments, natural solutions, mind-body connections, and investigating root causes of skin conditions for long-term benefits.

Education 52

Education Esthetician Medical Esthetics 52

The Dermatology Digest

MAY 2, 2024

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.

Pharmaceutical 74

Pharmaceutical Dermatitis Office Clinic 74

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Suggest the usage of crisaborole 2% ointment for mild to moderate atopic dermatitis. in a news release. “It

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

Aesthetics Advisor

OCTOBER 3, 2023

Doctors were confronted with a problem: some people simply didn't respond to the investigational treatment, which was offered after standard therapy failed. The disorder is typified by the three D's—dementia, diarrhea and dermatitis. Without treatment, which is simply providing niacin, pellegra can be fatal.

Therapy 36

Therapy Innovations Clinic Dermatitis 36

The Dermatology Digest

DECEMBER 15, 2023

Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Eczema 28

Eczema Dermatitis Safety Therapy 28

West Lake Dermatology

APRIL 8, 2024

Issues such as peri-orificial dermatitis, rosacea, and folliculitis are commonly mistaken for acne and as such they are not treated effectively. In this blog post, we will examine some common acne-like conditions and shed light on their causes, symptoms, similarities to acne , and appropriate treatments.

Rosacea 36

Rosacea Dermatitis Exfoliation Irritation 36